Literature DB >> 20638121

Cardiovascular effects of marine omega-3 fatty acids.

Palaniappan Saravanan1, Neil C Davidson, Erik B Schmidt, Philip C Calder.   

Abstract

Much evidence shows that the marine omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid have beneficial effects in various cardiac disorders, and their use is recommended in guidelines for management of patients after myocardial infarction. However, questions have been raised about their usefulness alongside optimum medical therapies with agents proven to reduce risk of cardiac events in high-risk patients. Additionally, there is some evidence for a possible pro-arrhythmic effect in subsets of cardiac patients. Some uncertainly exists about the optimum dose needed to obtain beneficial effects and the relative merit of dietary intake of omega-3 polyunsaturated fatty acids versus supplements. We review evidence for the effects of omega-3 polyunsaturated fatty acids on various cardiac disorders and the risk factors for cardiac disease. We also assess areas of uncertainty needing further research. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20638121     DOI: 10.1016/S0140-6736(10)60445-X

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  141 in total

Review 1.  The evidence for α-linolenic acid and cardiovascular disease benefits: Comparisons with eicosapentaenoic acid and docosahexaenoic acid.

Authors:  Jennifer A Fleming; Penny M Kris-Etherton
Journal:  Adv Nutr       Date:  2014-11-14       Impact factor: 8.701

2.  Roles of saturated vs. polyunsaturated fat in heart failure survival: not all fats are created equal.

Authors:  Ganesh V Halade; Yu-Fang Jin; Merry L Lindsey
Journal:  Cardiovasc Res       Date:  2011-11-08       Impact factor: 10.787

3.  Omega-3 oil: a fishy protection for the heart.

Authors: 
Journal:  Nat Med       Date:  2010-11       Impact factor: 53.440

4.  Effects of n-3 fatty acids on major cardiovascular events in statin users and non-users with a history of myocardial infarction.

Authors:  Simone R B M Eussen; Johanna M Geleijnse; Erik J Giltay; Cathy J M Rompelberg; Olaf H Klungel; Daan Kromhout
Journal:  Eur Heart J       Date:  2012-02-01       Impact factor: 29.983

5.  Clinical correlates and heritability of erythrocyte eicosapentaenoic and docosahexaenoic acid content in the Framingham Heart Study.

Authors:  William S Harris; James V Pottala; Sean M Lacey; Ramachandran S Vasan; Martin G Larson; Sander J Robins
Journal:  Atherosclerosis       Date:  2012-06-07       Impact factor: 5.162

6.  A short-term n-3 DPA supplementation study in humans.

Authors:  Eliza Miller; Gunveen Kaur; Amy Larsen; Su Peng Loh; Kaisa Linderborg; Harrison S Weisinger; Giovanni M Turchini; David Cameron-Smith; Andrew J Sinclair
Journal:  Eur J Nutr       Date:  2012-06-23       Impact factor: 5.614

Review 7.  Integrative Therapies and Cardiovascular Disease in the Breast Cancer Population: A Review, Part 2.

Authors:  Khara Lucius; Kristen Trukova
Journal:  Integr Med (Encinitas)       Date:  2015-10

8.  Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis.

Authors:  Srinivasan Dasarathy; Jaividhya Dasarathy; Amer Khiyami; Lisa Yerian; Carol Hawkins; Ruth Sargent; Arthur J McCullough
Journal:  J Clin Gastroenterol       Date:  2015-02       Impact factor: 3.062

9.  Joint effects of fatty acid desaturase 1 polymorphisms and dietary polyunsaturated fatty acid intake on circulating fatty acid proportions.

Authors:  Juan Juan; Hongyan Huang; Xia Jiang; Andres V Ardisson Korat; Mingyang Song; Qi Sun; Walter C Willett; Majken K Jensen; Peter Kraft
Journal:  Am J Clin Nutr       Date:  2018-05-01       Impact factor: 7.045

Review 10.  Does Supplementation with Omega-3 PUFAs Add to the Prevention of Cardiovascular Disease?

Authors:  Evangelos C Rizos; Moses S Elisaf
Journal:  Curr Cardiol Rep       Date:  2017-06       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.